Expertise in
8
conditions

Dr. Edward L. Lain

Dermatology
4300 N Quinlan Park Rd, Ste 225, 
Austin, TX 
Accepting New Patients
Expertise in
8
conditions
4300 N Quinlan Park Rd, Ste 225, 
Austin, TX 

Overview

Edward Lain is a Dermatologist practicing medicine in Austin, Texas.

Dr. Lain is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Actinic Keratosis, Acne, Plaque Psoriasis, and Neurocutaneous Melanosis.

Dr. Lain is board certified in The American Board Of Dermatology - Dermatology. He is actively involved in clinical research, co-authoring 7 peer reviewed articles and participating in 20 clinical trials. Dr. Lain is currently accepting new patients.

Specialties

Dermatology

Licenses

Dermatology in TX

Board Certifications

The American Board Of Dermatology - Dermatology

Hospital Affiliations

Ascension Seton Medical Center Austin
Ascension Seton Northwest
Ascension Seton Williamson
Dell Seton Medical Center At The University Of Texas

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
FirstCare
  • HMO
Freedom Life
  • INSURANCE PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Moda Health
  • EPO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sendero
  • HMO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
US Health and Life
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 27 Less Insurance Carriers -

Locations

Sanova Dermatology
4300 N Quinlan Park Rd, Ste 225, Austin, TX 78732

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: April 16, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 2/Phase 3
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Single-Arm, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults
A Multicenter, Single-Arm, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults
Enrollment Status: Completed
Publish Date: July 19, 2024
Intervention Type: Drug
Study Drugs: Duobrii, CeraVe, Topical Cream
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intralesional Injection of STP705 in Adult Patients With Cutaneous Squamous Cell Carcinoma in Situ (isSCC)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intralesional Injection of STP705 in Adult Patients With Cutaneous Squamous Cell Carcinoma in Situ (isSCC)
Enrollment Status: Completed
Publish Date: March 18, 2024
Intervention Type: Drug, Other
Study Drug: STP705
Study Phase: Phase 2
A Prospective, Multicenter, Randomized, Evaluator-Blinded, Study to Evaluate the Safety and Efficacy of AMZEEQ® Companion Treatment With Oral Isotretinoin Therapy in Patients With Moderate to Severe Acne Vulgaris
A Prospective, Multicenter, Randomized, Evaluator-Blinded, Study to Evaluate the Safety and Efficacy of AMZEEQ® Companion Treatment With Oral Isotretinoin Therapy in Patients With Moderate to Severe Acne Vulgaris
Enrollment Status: Completed
Publish Date: June 22, 2023
Intervention Type: Drug
Study Drugs: Isotretinoin, Amzeeq
Study Phase: Phase 4
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis: The ADmIRe Study
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis: The ADmIRe Study
Enrollment Status: Terminated
Publish Date: April 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

7 Total Publications

Red light photodynamic therapy with 10% aminolevulinic acid gel showed efficacy for treatment of superficial basal cell carcinoma in a randomized, vehicle controlled, double-blind, multicenter phase III study.
Red light photodynamic therapy with 10% aminolevulinic acid gel showed efficacy for treatment of superficial basal cell carcinoma in a randomized, vehicle controlled, double-blind, multicenter phase III study.
Journal: Journal of the American Academy of Dermatology
Published: May 22, 2025
Similar Doctors
Expertise in
56
conditions
Expertise in
56
conditions
Referral may be required

Austin Diagnostic Clinic - Westlake

1250 S Capital Of Texas Hwy Bldg 3, 
West Lake Hills, TX 
 (7.9 miles away)
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Stacia Miles is a Dermatologist practicing medicine in West Lake Hills, Texas. Dr. Miles is highly rated in 56 conditions, according to our data. Her clinical expertise encompasses Pustules, Syringocystadenoma Papilliferum, Syringoma, and Sebaceous Adenoma. Dr. Miles is currently accepting new patients.

Expertise in
22
conditions
Expertise in
22
conditions
Referral required
Before you request

Vitalogy Skincare CP

1464 E Whitestone Blvd Ste 301, 
Cedar Park, TX 
 (9.2 miles away)
512-260-3376
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Tricia Winters is a Dermatologist practicing medicine in Cedar Park, Texas. Dr. Winters is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Keratitis-Ichthyosis-Deafness Syndrome, Netherton Syndrome, Ichthyosis Bullosa of Siemens, and Peeling Skin Syndrome. Dr. Winters is currently accepting new patients.

Expertise in
71
conditions
Expertise in
71
conditions
Referral may be required
Before you request

Austin Regional Clinic PA

3828 S 1st St, 
Austin, TX 
 (12.7 miles away)
512-443-1311
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Steven Rasmussen is a Dermatologist practicing medicine in Austin, Texas. Dr. Rasmussen is highly rated in 71 conditions, according to our data. His clinical expertise encompasses Trichoepithelioma, Multiple Familial Trichoepithelioma, Syringoma, and Sebaceous Adenoma. Dr. Rasmussen is currently accepting new patients.

Frequently Asked Questions about Dr. Edward L. Lain

How do I make an appointment with Dr. Edward L. Lain?

You can book an appointment with Dr. Edward L. Lain by calling their office at 512-266-0007. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Edward L. Lain a top-rated expert for Actinic Keratosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Edward L. Lain is classified as an Distinguished expert for Actinic Keratosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Edward L. Lain specialize in?

While Dr. Edward L. Lain is a Dermatology, they have specific expertise in Actinic Keratosis, Acne, and Plaque Psoriasis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Edward L. Lain participate in research or clinical trials?

Yes. Dr. Edward L. Lain has published 7 articles and abstracts on conditions like Actinic Keratosis. You can view a list of Dr. Edward L. Lain's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Edward L. Lain accept my insurance?

Dr. Edward L. Lain accepts most major insurance plans, including Aetna and Alliant Health. We recommend calling the office directly at 512-266-0007 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lain's expertise for a condition
ConditionClose
    View All 23 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile